Study to Evaluate ASN008 Topical Gel (TG)
Study to Evaluate ASN008 Topical Gel (TG)
This is an ascending dose escalation study to test the safety, tolerability and preliminary
 efficacy of ASN008 TG in first-in-human subjects
This is a two part, randomized, blinded, vehicle-controlled study to determine a safe and
 tolerable dose of ASN008 TG. Part A will asses a single ascending dose of ASN008 TG in
 cohorts of healthy volunteers, while Part B will assess multiple ascending doses of TG, to be
 determined (TBD) based on Part A safety and tolerability, in patients with mild-to-moderate
 dermatitis. Results from Part A and B will characterize safety, tolerability and
 pharmacokinetics. Part B patients will be assessed for changes in pruritus based on a
 numerical rating scale (NRS) of pruritus at baseline and on Day 15.
Inclusion Criteria:

 Part A - Healthy Volunteers:

 -  Written informed consent obtained prior to any required study-related procedure

 -  Healthy female or male subject aged 18 to 65

 -  Willing to use medically effective methods of birth control

 -  Females of reproductive potential must have a negative serum pregnancy test at
 screening and negative serum or urine pregnancy test prior to first study drug
 application on Day 1

 -  Non-smoker (no nicotine products for at least 6 months prior to screening)

 -  BMI ≥18.5 kg/m2 and ≤32.0 kg/m2 with minimum weight of 60 kg

 Part B- Subjects with AD:

 -  Written informed consent obtained prior to any required study-related procedure

 -  Confirmed diagnosis of active atopic dermatitis (AD)

 -  History of AD for at least 6 months prior to Day 1 with an investigator global
 assessment ≥3 and body surface area covered with 1-10% AD

 -  Pruritus score (NRS)≥ 5 at screening and NRS ≥7 on Day 1

 Exclusion Criteria:

 Both Part A and Part B:

 -  Pregnant or breast-feeding women

 -  Skin disease that may interfere with study assessments

 -  Febrile illness within 6 days prior to Day 1, history of cancer within 5 years of Day
 1, major surgery within 8 weeks prior to Day1, known immunodeficiencies, positive for
 hepatitis B or C or HIV infection

 -  Significant medical/surgical history or condition or current physical/laboratory/ECG/
 vitals signs abnormality that might compromise the subject

 -  Corrected QT duration ≥450 milliseconds or other significant ECG abnormality

 -  Received marketed or investigational biological agent within 12 weeks prior to Day 1
 or JAK inhibitor or nonbiological product or device within 4 weeks of Day 1 or within
 8 weeks of Day 1 if investigational product used or any drug/ substance that is a
 strong inhibitor or inducer of CYP3A4 or CYP2D6

 -  Suspected hypersensitivity/allergy to lidocaine

 -  Significant drug or alcohol abuse or mental illness in 2 years prior to Day 1

 Part A Only- Healthy Volunteers:

 -Used medications or skin emollients within 2 weeks prior to Day 1 unless approved by
 investigator and sponsor

 Part B Only - Subjects with AD:

 -  Has infected atopic dermatitis

 -  Used dupilumab 12 weeks prior to Day 1

 -  Used doxepin, hydroxyzine or diphenhydramine, urea containing topical products within
 1 week prior to Day 1

 -  Used systemic antibiotics or topical medicated treatment or other systemic treatments
 that could affect AD 2 weeks prior to Day 1

 -  Received any UV-B phototherapy, excimer laser treatment or psoralen-UV-A treatment
 within 4 weeks prior to Day 1